Aug 11, 2017
Natural killer cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and virally infected cells. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also gener...
Read More...
Jun 14, 2017
Almost 6,000 new cases of acute lymphoblastic leukemia, or ALL, are expected to be diagnosed this year in the United States. Up to 30 percent of adult acute lymphoblastic leukemia or ALL patients have Philadelphia chromosome, where two segments of chromosomes have aberrantly fused together. Adult ALL patients often ...
Read More...
Jun 07, 2017
In the quest for personalized therapies, most research has focused on how an individual’s genome controls their body’s responses to drugs. However, there is increasing evidence that a person’s unique microbiome — the population of bacteria and other microbes that live in their body — can be key to determining whethe...
Read More...
May 25, 2017
Merck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...
Read More...
May 24, 2017
The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and...
Read More...
May 08, 2017
For more information, Please click Ovarian Cancer Market.
Read More...
May 02, 2017
FDA Approves Alunbrig (brigatinib) for Rare Lung Cancer Takeda Pharmaceuticals announced the FDA approved Alunbrig (brigatinib) to treat patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Brigatinib is a kinas...
Read More...
Apr 21, 2017
Chemotherapy-induced nausea and vomiting (CINV) are severe side effects of cancer treatment which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles/ refuse further treatment due to fear of future nausea and vomiting. It is classified as Anticipatory, Acute, D...
Read More...
Apr 13, 2017
Cancer, diabetes and eczema star in 2017 top-launch list Launch prognostications are getting more attention than ever as they come out with “Drugs to Watch” list, and the highlights of different drugs shows what might work this year. By 2021, some of the drugs in the list are expected to bring in $16 billion, shared...
Read More...
Mar 29, 2017
Nearly two-thirds of the mutations that drive cancers are caused by errors that occur when cells copy DNA. The findings, published in Science are the latest argument in a long-running debate over how much the environment or intrinsic factors contribute to cancer. They also suggest that many cancer mutations are not ...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper